We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Martin Shkreli arriving at Federal Court in Brooklyn with his lawyer Benjamin Brafman. SIPA USA/PA Images

'Bad boy of pharma' Martin Shkreli goes on trial for fraud

Martin Shkreli rose to infamy after raising the price of HIV drug Daraprim from $13.50 a pill to $750.

MARTIN SHKRELI, THE former pharmaceutical executive dubbed “the most hated man in America” for his astronomical price hikes on an AIDS treatment, arrived today at a federal court to face fraud charges.

Shkreli (34) who rose to infamy after raising the price of HIV drug Daraprim from $13.50 a pill to $750, has pleaded not guilty to accusations he propagated a Ponzi-like fraud on investors. He faces up to 20 years in prison if convicted, according to US prosecutors in Brooklyn.

Shkreli generated widespread public scorn for seeming to take glee in becoming the so-called “bad boy” of pharma for raising prices and later smirking through a congressional hearing scrutinising his actions.

As he arrived at the courthouse, Shkreli was followed by dozens of photographers and cameramen. He was accompanied by his attorney, Ben Brafman, who defended former International Monetary Fund chief Dominique Strauss-Kahn from charges of sexual assault in 2011.

Jury selection was expected later today before Judge Kiyo Matsumoto. The trial is expected to last about a month.

Shkreli allegedly used $11 million in stock from his first pharma company Retrophin to pay off investors who lost money in two of his hedge funds, prosecutors say.

The case does not focus on his price hike of Daraprim while he was chief executive of Turing Pharmaceuticals, which has become a rallying cry of pharmaceutical industry critics who have called on tighter rules to prevent price gouging.

Shkreli resigned from Turing shortly after his indictment in December 2015 after which he was released from prison on bond.

In recent months, Shkreli has been back in the news after student protests led to the cancellation of an appearance at the University of California at Davis.

Comments have been disabled for legal reasons 

© AFP 2017

Read: Man who hiked price of HIV drug mocks schoolkids for recreating medicine in lab

Read: Man whose company hiked cost of life-saving drug arrested on fraud charges